Please login to the form below
Oesophageal cancer
This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.
Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer
Merck &Co’s – known as MSD outside the US and Canada – Keytruda has received an approval from the US Food and Drug Administration (FDA) for the treatment of advanced oesophageal cancer. . ... status. “There have been few advances in improving
Latest news
-
BMS aims for US approval of Opdivo combo in stomach cancer
The US regulator will review the combo treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or oesophageal adenocarcinoma (EAC). ... free survival (PFS) in patients with
-
Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation
such as stage III NSCLC and locally advanced oesophageal cancer. ... On top of these studies, tiragolumab is being evaluated in metastatic oesophageal squamous cancer and cervical cancer.
-
BMS’ Opdivo wins EU approval for second-line oesophageal cancer
The US Food and Drug Administration (FDA) has already approved Opdivo for second-line advanced oesophageal cancer treatment, giving the immunotherapy a green light in June. ... Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD)
-
Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
Merck &Co/MSD’s checkpoint inhibitor Keytruda cut the risk of disease progression or death by 35% in patients with locally advanced or metastatic oesophageal and gastroesophageal junction (GEJ) cancer. ... Merck’s main rival in oesophageal cancer is
-
Merck signs separate agreements with Seattle Genetics for two cancer drugs
head and neck, oesophageal and gastric cancer. ... Ladiratuzumab vedotin binds to LIV-1 on cancer cells, where it then releases a cell-killing agent into the target cells upon internalisation.
BMS aims for US approval of Opdivo combo in stomach cancer
Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation
BMS’ Opdivo wins EU approval for second-line oesophageal cancer
Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
Merck signs separate agreements with Seattle Genetics for two cancer drugs
More from news
Approximately 6 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Deal Watch March 2016
Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory
20 for 2020 – Five pharma companies to watch
Chinese biotech’s global ambitions
Deal Watch March 2016
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Publications Director
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Senior Account Executive
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Medical Writer
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Medical Editor
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
